Ulrich M. Zanger - Concepedia

Author

Ulrich M. Zanger

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology ORCID

Also Known As

Aleksunes, Lauren M., Love, Sharon, U M Zanger, U ZANGER, U Zanger, U. M. Zanger, U. Zanger, U.M . Zanger, U.M. Zanger, ULRICH M. ZANGER

245

Publications

26.5K

Citations

H-Index

165

Concepts

All Affiliations

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology University of Tübingen Charité - Universitätsmedizin Berlin Robert Bosch (Germany)Humboldt-Universität zu Berlin

About

Ulrich M. Zanger is an author at Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology specializing in medicine, pharmacology, and genetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	62	6.6K
2	Natural Sciences	14	15	1K
3	Health Sciences	11	11	1.2K
4	Public Health	4	4	1K
5	Engineering	3	3	60

Ulrich M. Zanger

165

Publications

18.4K

Citations

H-Index

Page 1

	Year	Citations
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism Frank J. Gonzalez, Radek C. Skodat, Shioko Kimura, Nature BiologyMendelian DisorderGenetic DisorderGeneticsInherited Metabolic Disease	1988	715
The genetic determinants of the CYP3A5 polymorphism Elisabeth Hustert, Michael Haberl, Oliver Burk, Pharmacogenetics	2001	670
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Thomas Lang, Kathrin Klein, Joachim E. Fischer, Pharmacogenetics	2001	569
Sex Is A Major Determinant of Cyp3a4 Expression in Human Liver Renzo Wolbold, Kathrin Klein, Oliver Burk, Hepatology Systems BiologyHepatologyCyp3a4 ExpressionLiver PhysiologyGenetics	2003	495
Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes Werner Schroth, Lydia Antoniadou, Péter Fritz, Journal of Clinical Oncology	2007	465
Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants Elke Schaeffeler, Christine Fischer, D. Brockmeier, Pharmacogenetics GeneticsGenetic EpidemiologyHuman PolymorphismPathologyLarge Population	2004	417
Nomenclature for human CYP2D6 alleles Ann K. Daly, Jürgen Brockmöller, Franck Broly, Pharmacogenetics BiologyGenetic AnalysisAllelic VariantSeparate AlleleGenetic Disorder	1996	399
Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group Matthias Schwab, Ulrich M. Zanger, Claudia Marx, Journal of Clinical Oncology	2008	392
Expression of Organic Cation Transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) Is Affected by Genetic Factors and Cholestasis in Human Liver† Anne T. Nies, Hermann Koepsell, Stefan Winter, Hepatology	2009	380
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance Ulrich M. Zanger, Kathrin Klein Frontiers in Genetics Cyp2b6 PolymorphismGeneticsHuman PolymorphismMolecular GeneticsMinor Drug	2013	345

Page 1